

## ASX Announcement

5 June 2026

### ReNerve appoints UG Medical as distribution partner for Malaysian market

#### Key Highlights

- Distribution agreement executed with UG Medical, an established medical device distributor with an extensive network across Malaysia
- Agreement covers the Malaysian market, with a population of approximately 33 million people, and a rapidly growing healthcare sector
- NervAlign received regulatory clearance in Malaysia earlier this year via the Medical Device Authority (MDA)

**ReNerve Limited** (ASX, "ReNerve" or "the Company"), an Australian biotechnology company developing innovative products for peripheral nerve injury ("PNI") repair, announced today that it has partnered with UG Medical as its commercialisation partner for the NervAlign products in the Malaysian market.

Under the terms of the agreement, UG Medical Services Sdn Bhd (UG Medical) will be responsible for the importation, regulatory management and warehousing and will work with the ReNerve team across marketing, sales and distribution of the NervAlign product range within Malaysia. ReNerve has its NervAlign Nerve Cuff approved in Malaysia and is looking to launch its nerve conduit product later this year. ReNerve will provide ongoing clinical and technical support, product training and regulatory liaison to support UG Medical's commercialisation activities. The agreement has an open-ended term and is on customary commercial terms for medical device distribution arrangements.

Commercialisation in Malaysia with UG Medical will be supported by ReNerve's Asia sales and marketing team, who has already built relationships with hospitals in the region. Additionally, ReNerve will be a major sponsor for the hand surgery teaching event in Kuala Lumpur in June 2026<sup>1</sup>.

"This agreement with UG Medical represents a compelling opportunity to establish NervAlign in the Malaysian market, which is one of Southeast Asia's most progressive and well-developed healthcare systems. UG Medical's relationships and in-market expertise make them an outstanding partner for ReNerve as we continue to build our commercial presence across the Asia-Pacific region," said Dr Julian Chick, CEO of ReNerve.

"NervAlign addresses a significant and underserved clinical need in peripheral nerve repair and Malaysia's growing investment in surgical infrastructure and specialist care creates a strong environment for adoption. We look forward to working with the UG Medical team to bring NervAlign to surgeons and patients across Malaysia."

<sup>1</sup> <https://essermasterclass.com/hand-surgery-course-asia-2026/>



## About UG Medical

UG Medical is a Kuala Lumpur-based medical device company specialising in the distribution and commercialisation of medical technologies across Malaysia. With an established presence across hospitals and healthcare facilities nationally, UG Medical has a strong track record of introducing innovative medical devices to the Malaysian market and supporting clinical adoption through education and specialist engagement.<sup>2</sup>

## Malaysian Market Opportunity

Malaysia represents one of Southeast Asia's fastest-growing healthcare markets, supported by both a well-developed public hospital network and an expanding private healthcare sector. The Malaysian government has committed to significant ongoing investment in healthcare infrastructure under its 12th Malaysia Plan framework, with particular focus on surgical capability and specialist services<sup>3</sup>.

- ENDS -

**This announcement has been approved for release by the Company's Board of Directors.**

**For further information and enquiries, please contact:**

**Dr Julian Chick**

CEO & Managing Director

ReNerve Ltd

+61 (03) 9482 3940

[info@renerve.com.au](mailto:info@renerve.com.au)

**Matthew Wright**

Investor & Media Relations

NWR Communications

+61 (0) 451 896 420

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

---

<sup>2</sup> <https://www.ugmedical.com/>

<sup>3</sup> <https://rmke12.ekonomi.gov.my/en>


## About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

### Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

### Comparison of Patient Pre & Post Surgery Pain Score



Standard of Care vs NervAlign™ Nerve Cuff Protected Nerve Repairs

The comparison of pain scores between the two cohorts of patients

For personal use only

## Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions and related surgical repairs:

### *On market*

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Empliq™ Deep Dermal tissue product** -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Empliq™ Amniotic tissue product ranges** -- Three amniotic tissue product ranges used to aid the healing of wounds.

### *In development*

- **NervAlign® Nerve Conduit Range** – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

## Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching \$271k in sales and YTD FY2026 sales revenues showing further significant increases across its portfolio. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.6 billion in 2024 and is projected to reach \$6.2 billion by 2031.<sup>4</sup>

## Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

---

<sup>4</sup> Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)